This Week Last Year in Medtech: April 16 – 22

See what Natus Medical, J&J, and AstraZeneca were up to this time last year.

Katie Hobbins, Managing Editor

April 20, 2023

2 Min Read
Calendar pages
Archive Holdings Inc. / The Image Bank via Getty Images

Natus Medical To Go Private Amid Supply Chain Woes

The company got slammed with $3.4 million of "extraordinary" supply chain costs associated with buying semiconductors in the first quarter. Now, a private equity firm is buying Natus for about $1.2 billion.

Accelus and CHP Merger End SPAC Merger Plans

The two companies join a growing list of firms that have abandoned Special Purpose Acquisition Corporation mergers in recent months.

Financings Still Alive & Well in Orthopedics

Carlsmed has raised $30 million in a series B round.

Patient-Centric Prefilled Syringe Aims to Improve Injection Experience

Ipsen shares patient-reported data on its patient-centric prefilled syringe and announces plans for its next-generation delivery system.

J&J Medtech Execs Say Strategic Merit, Not Size, Matters in M&A

The company continues to evaluate potential M&A deals in medical devices.

Covestro Debuts Proof-of-Concept Drug Delivery Device

The sustainable demo product highlights the company’s medical-grade polycarbonates.

AstraZeneca Pushes Deeper into CDx Space with New Collaboration

The Cambridge, UK-based company is teaming up with Amoy Diagnostics to develop CDx offerings.

Consider Biosynthetic Cellulose for Wound Management, Implants, & Drug Delivery

The bioengineered material can supply high levels of moisture as well as absorb drug solutions or emulsions, according to JeNaCell – An Evonik Company, whose experts will be speaking in an upcoming webinar.

Abbott's Diversified Portfolio Is Its Secret Sauce

The company's COVID-19 test sales surged in the first quarter to $3.3 billion, but Abbott has shown that its core business is also going strong.

CairnSurgical to Supply 3D Printed Breast Cancer Locator in Europe

Surgical guide designed to reduce the incidence of positive margins after breast cancer surgery.

Better Therapies for Severe Heart Disease

Serious heart disease, and myocardial infarction requires a search for advanced therapy and medical device.

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like